Sanofi invests €170 million in new vaccine
production facility in France
- Expansion at Val de Reuil reinforces the
company's position as a global leader in seasonal flu vaccines
-
Paris, France - October 12, 2017 - Sanofi
is investing €170 million to expand a vaccine manufacturing site in
Val de Reuil, France. The expansion further strengthens Sanofi's
position as one of the world's leading seasonal flu vaccine
providers.
The new facility will allow Sanofi Pasteur, the
Vaccines global business unit of Sanofi, to expand supply of
VaxigripTetra® to up to 70 countries in six continents. The new
quadrivalent influenza vaccine contains two A strains and two B
strains of influenza virus, as per World Health Organization
recommendation.
"Influenza continues be a major public health
problem around the world, causing serious complications,
hospitalizations and deaths, mostly for certain high-risk
individuals," said David Loew, Executive Vice President, Sanofi,
and Head of Sanofi Pasteur. "As a global leader in flu vaccines,
this expansion reinforces Sanofi Pasteur's ability to tackle this
underestimated health challenge."
"This project brings together the expertise of
our people with our leading industrial know-how and illustrates our
commitment to manufacturing excellence solutions," said Philippe
Luscan, Executive Vice President, Global Industrial Affairs,
Sanofi. "Our investment underlines Sanofi's intent to strengthen
our industrial capacities in France as a major centre of influenza
vaccines production for worldwide markets."
The new Val de Reuil facility will be
the only site of its kind in France and Sanofi Pasteur remains the
sole influenza vaccine producer in the country.
This investment is one of several major capital
expenditures Sanofi has made in recent years to improve and expand
its vaccine production capacities across France, the United States
and Mexico.
Sanofi plans to complete the expansion by 2021,
subject to relevant health authority approvals, and will begin
producing vaccines in this new facility in 2022.
About the Val de Reuil Manufacturing
SiteThe Val de Reuil manufacturing site is among world leaders
in influenza vaccine production. It was founded in 1973 in the
Normandy Region of France, 100 km northwest of Paris. It covers all
the steps involved in manufacturing a vaccine: antigen production,
formulation, stages of pharmaceutical preparation (filling,
inspection and packaging) and quality control. The site also
includes Sanofi Pasteur's global vaccine distribution center and
ships around 900 million vaccine doses worldwide each year.
About VaxigripTetra®VaxigripTetra® is a
four-strain influenza vaccine, containing two A strains (A/H1N1 and
A/H3N2) and two B strains (B/Victoria and B/Yamagata) of influenza
virus, as per WHO recommendation. VaxigripTetra® is indicated for
adults and children from 3 years and older. It is a recent addition
to Sanofi Pasteur portfolio of influenza vaccines. Vaxigrip Tetra®
is already available in 20 European markets and additional launches
around the world are planned in the years ahead.
About InfluenzaSeasonal influenza or
"Flu" is an acute viral infection caused by influenza viruses,
spreading easily from person to person and circulating year-round
worldwide. Seasonal influenza is characterized by a sudden onset of
fever, cough (usually dry), headache, muscle and joint pain, severe
malaise (feeling unwell), sore throat and a runny nose. The cough
can be severe and can last 2 or more weeks. Most people recover
from fever and other symptoms within a week without requiring
medical attention. But influenza can cause severe illness or death
especially in people at high risk. The highest risk of
complications occur among pregnant women, children aged 6-59
months, the elderly, individuals with specific chronic medical
conditions such as diabetes, HIV/AIDS, asthma, and chronic heart or
lung diseases.[1]
According to the World Health Organization's
(WHO) estimates, the influenza annual global attack rates are
estimated at 5-10% in adults and 20-30% in children[2]. Worldwide,
annual influenza epidemics result in three to five million cases of
severe illness, and 250,000 to 500,000 deaths[3].
About Sanofi PasteurSanofi Pasteur
produces 200 million doses of vaccines against seasonal influenza
each year on its four sites: Swiftwater (Pennsylvania, United
States), Val de Reuil (France), Ocoyoacac (Mexico City, Mexico) and
Shenzhen (China). Sanofi Pasteur's seasonal influenza vaccines are
licensed and distributed in more than 150 countries. More than 3.5
billion doses of Sanofi Pasteur seasonal influenza vaccines have
been distributed worldwide over the past 60 years.
About Sanofi Sanofi, a global healthcare
leader, discovers, develops and distributes therapeutic solutions
focused on patients' needs. Sanofi is organized into five global
business units: Diabetes and Cardiovascular, General Medicines and
Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer
Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New
York (NYSE: SNY).
Sanofi Forward-Looking Statements This
press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
"expects", "anticipates", "believes", "intends", "estimates",
"plans" and similar expressions. Although Sanofi's management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
Sanofi's ability to benefit from external growth opportunities
and/or obtain regulatory clearances, risks associated with
intellectual property and any related pending or future litigation
and the ultimate outcome of such litigation, trends in exchange
rates and prevailing interest rates, volatile economic conditions,
the impact of cost containment initiatives and subsequent changes
thereto, the average number of shares outstanding as well as those
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in
Sanofi's annual report on Form 20-F for the year ended December 31,
2016. Other than as required by applicable law, Sanofi does not
undertake any obligation to update or revise any forward-looking
information or statements.
Contacts:
Media
RelationsLaurence BollackTel. : +33 (0)1 53 77 46
46mr@sanofi.com |
Investor RelationsGeorge GrofikTel.: +33 (0)1 53 77 45
45ir@sanofi.com |
[1] WHO fact sheet dated Nov. 2016 -
http://www.who.int/mediacentre/factsheets/fs211/en/
[2] WHO. Weekly epidemiological record - Vaccines against
influenza WHO position paper, 87, No. 47 p461-476. November 23,
2012. Available at: http://www.who.int/wer/2012/wer8747/en/
[3] WHO Influenza Factsheet: Influenza (Seasonal).
http://www.who.int/mediacentre/factsheets/fs211/en/
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/9589f159-d617-48e8-82c2-b6fe76aedab3
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024